ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Viniferin and its derivatives: a comprehensive review of structural variations and promising pharmacological applications in disease prevention and therapeutic development.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Effect of Viniferin on Liver Cancer: Research Based on Network Pharmacology, Molecular Docking and Molecular Dynamics Simulation.Medical sciences (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viniferin, a resveratrol-derived compound that belongs to a group of plant-produced stilbenoids, functions as a natural defense against microbial invasion, toxins, infections, and ultraviolet radiation. Alpha-(α-) viniferin (trimer), beta-(β-) viniferin (dimer), delta-(δ-) viniferin (oxidative dehydrodimer), epsilon-(ε-) viniferin (distinct dehydrodimer), gamma-(γ-) viniferin (isomeric oligomer), vitisin A (R-viniferin), and vitisin B (R2-viniferin) are structurally diverse forms with distinct pharmacological activities. Antioxidant studies showed that ε-viniferin exhibited a 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging half-maximal inhibitory concentration (IC₅₀) of about 80 µM. Also, suppression of nuclear factor kappa B, cyclooxygenase-2, and prostaglandin E₂ are anti-inflammatory mechanisms. R2-viniferin demonstrated an IC₅₀ of 9.7 µM against hepatocellular carcinoma HepG2 cells at 72 h, mediated through apoptosis and cell-cycle arrest, according to anticancer studies that demonstrated dose-dependent cytotoxicity. There have been reports of additional activity against models of glioblastoma and prostate cancer. In metabolic disorders, oral α-viniferin (20-40 mg/kg/day) improved lipid and glucose homeostasis in mice fed a high-fat diet, and it additionally improved liver and renal biomarkers such as blood urea nitrogen, creatinine, alanine aminotransferase, and aspartate aminotransaminase. Several bacterial strains have shown signs of preliminary antimicrobial action. By reducing excitotoxicity and oxidative stress, viniferins also have neuroprotective effects. They also have anti-melanogenic properties by blocking the tyrosinase and melanogenesis pathways. Collectively, viniferins demonstrate pleiotropic pharmacologic activities by defined molecular mechanisms and quantifiable dose-dependent effects. The properties classify viniferins as new multifunctional drug candidates for discovery and nutraceuticals, but they highlight the need for standardized pharmacologic assays, further preclinical validation, and pharmacokinetic optimization towards clinical use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.